Angle appoints Juliet Thompson to its Board as Non-Executive Director

– UK, Guildford –  ANGLE plc (LON: AGL | OTC: ANPCY), a world-leading liquid biopsy company, today announced the appointment of Juliet Thompson to its Board as a Non-Executive Director, effective from 5 January 2023.

“I am delighted that Juliet has agreed to join the Board of ANGLE at such an exciting time in our commercial development. Juliet has extensive experience in the life science sector and will strengthen the Board with her entrepreneurial expertise and deep knowledge of capital markets,” said Board Chairman, Garth Selvey.

About Juliet Thompson

Juliet Thompson has spent much of her career advising companies in the international life sciences sector, completing multiple financing and M&A transactions in Europe and the United States, and helping companies raise more than US $4 billion to pursue their growth strategies. Juliet has held senior positions at WestLB Panmure and Stifel Europe and in 2003 was a co-founder of the specialist life science investment bank, Code Securities, later acquired by Nomura.

Juliet Thompson currently has several roles, including Non-Executive Board positions at Indivior plc, Novacyt SA, and the private company, OrganOx. She chairs the Audit Committees of all three companies and is a member of the remuneration and nomination committees.

Juliet Thompson said: “As a founder of two businesses and with a long track record advising companies, I understand the challenges faced by executive management teams of growth companies. I have specialist knowledge in the areas of financing, strategy, and corporate governance and I look forward to bringing this experience to ANGLE as the Company looks further to advance its world-leading position in CTC liquid biopsy.”

About ANGLE plc

ANGLE is a world-leading liquid biopsy company with sample-to-answer solutions. ANGLE’s proven patent-protected circulating tumor cell harvesting technology is known as the Parsortix system.

ANGLE’s Parsortix system is FDA-cleared for its intended use in metastatic breast cancer and is currently the first and only FDA-cleared medical device to harvest intact circulating cancer cells from the blood.

For more information: https://www.angleplc.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.